Beacon Investment Advisory Services Inc. Decreases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Beacon Investment Advisory Services Inc. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 3,721 shares of the biopharmaceutical company’s stock after selling 680 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Alnylam Pharmaceuticals were worth $876,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after acquiring an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 3.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after purchasing an additional 16,756 shares during the last quarter. Swiss National Bank lifted its position in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after purchasing an additional 1,000 shares during the last quarter. Eagle Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 25.7% during the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after purchasing an additional 63,385 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 0.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 278,241 shares of the biopharmaceutical company’s stock worth $76,525,000 after purchasing an additional 1,294 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In related news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. This represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,122 shares of company stock worth $2,540,455. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $275.54 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm has a market cap of $35.54 billion, a PE ratio of -105.17 and a beta of 0.34. The business’s fifty day simple moving average is $246.27 and its 200-day simple moving average is $260.10. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the previous year, the company earned $1.15 EPS. The company’s revenue for the quarter was down 33.3% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.18 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ALNY. Sanford C. Bernstein decreased their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Needham & Company LLC reissued a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.